Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021814 · ClinicalTrials.gov registry record · Phase 3
Medical Therapy of Prostatic Symptoms
A Phase 3 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 3
- Development phase
- 3,407
- Enrollment target
NCT00021814 is a Phase 3 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 3,407 participants.
The verdict
NCT00021814, a Phase 3 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,407 participants
- Enrollment target
Study Summary
The Medical Therapy of Prostatic Symptoms (MTOPS) is a clinical research study sponsored by the National Institutes of Health (NIH). The study will test whether the oral drugs finasteride (Proscar) and doxazosin (Cardura), alone or together, can delay or prevent further worsening of symptoms in men with Benign Prostatic Hyperplasia (BPH). MTOPS is the largest and longest study to simultaneously test whether these drugs can delay or prevent the clinical progression (symptom worsening) of BPH. Seventeen U.S. medical centers recruited 2,931 men diagnosed with symptomatic BPH between December 1995 and March 1998. Study doctors will continue to follow these men through November 2001 on a quarterly basis. In addition to the clinical progression of BPH, MTOPS will include evaluations of prostate volume by ultrasound, prostate biopsies among a subgroup of volunteers, and quality of life.
Interventions
- DRUG Doxazosin
- DRUG Finasteride
- DRUG Doxazosin placebo
- DRUG Finasteride placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,407 participants |
| Start Date | 1995-12 |
| Est. Completion | 2001-11-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00021814
The ClinicalTrials.gov registry entry for NCT00021814 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,407 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Doxazosin is the first listed.
NCT00021814 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00021814 about?
NCT00021814 is a clinical study titled "Medical Therapy of Prostatic Symptoms". The Medical Therapy of Prostatic Symptoms (MTOPS) is a clinical research study sponsored by the National Institutes of Health (NIH). The study will test whether the oral drugs finasteride (Proscar) and doxazosin (Cardura), alone or together, can delay or prevent further worsening of symptoms in men ...
What is the current status of trial NCT00021814?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,407 participants. The study started on 1995-12. Estimated completion is 2001-11-30.
What interventions are being tested in trial NCT00021814?
The interventions under investigation include: Doxazosin (DRUG), Finasteride (DRUG), Doxazosin placebo (DRUG), Finasteride placebo (DRUG).
Who is sponsoring clinical trial NCT00021814?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.